Abstract
Parathyroid hormone (PTH) stimulates bone resorption as well as bone formation in vivo and in organ culture. The catabolic actions of PTH have been recognized in patients with hyperparathyroidism, or with acute infusion of the N-terminal 1–34 fragment of human PTH (hPTH1–34). Whereas the anabolic actions of daily injection with PTH have been well studied in both humans and mice, the catabolic actions of PTH on murine bone remain to be defined. To do this we sought to create a model with short-term, sustained hyperparathyroidism using osmotic infusion pumps. We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1–34 (8.1 pmol/0.25 μl per h, equivalent to 40 μg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps. Bone mineral density (BMD), serum total calcium, hPTH1–34, mouse intact PTH (mPTH1–84), osteocalcin and mouse tartrate-resistant acid phosphatase (mTRAP) activity, and microarchitectural variables of the distal femur were measured. Separately, we compared the effects of intermittent daily injection of hPTH1–34 (40 μg/kg per day) with continuous infusion of hPTH1–34 on BMD and bone markers. Exogenous hPTH1–34 was detected only in the PTH-infused mice. Both intermittent and continuous treatment with hPTH1–34 markedly suppressed endogenous mPTH1–84, but only the latter induced hypercalcemia. Daily PTH injection significantly increased both serum osteocalcin and mTRAP, while continuous PTH infusion showed a strong trend to stimulate mTRAP, with a slight but non-significant increase in osteocalcin. There were significant differences in BMD at all sites between animals treated with the same daily dose of intermittent and continuous hPTH1–34. Microcomputed tomography (μCT) analysis of the distal femurs revealed that hPTH1–34 infusion significantly decreased trabecular connectivity density (P<0.05). Thus, the murine bone response to continuous PTH infusion was quite different from that seen with daily PTH injection. Short-term infusion of hPTH1–34 appears to be a good model to study the mechanisms underlying the catabolic action of PTH in mice.
Introduction
In humans, continuous elevation of serum parathyroid hormone (PTH) level, as in patients with primary hyperparathyroidism, is catabolic to bone (Cosman et al. 1991, Grey et al. 1996, Bilezikian & Silverberg 2004, Bilezikian et al. 2005). On the other hand, intermittent daily injection with the N-terminal 1–34 fragment of human PTH (hPTH1–34) is an approved anabolic therapy for the treatment of osteoporosis (Reeve et al. 1980, Lindsay et al. 1997, Duan et al. 1999, Cosman et al. 2001, Chen et al. 2003, Finkelstein et al. 2003, Fukata et al. 2004, Dobnig 2004). Infusion of hPTH1–34 (0.55 U/kg per h or 25 μg/24 h) to normal and osteoporotic women suppressed endogenous intact human PTH (hPTH1–84) secretion, decreased bone formation and increased bone-resorption markers (Cosman et al. 1991). Chen et al.(2003) compared bone mass and structure among patients with hyper- and hypoparathyroidism and control subjects by dual-energy X-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT), and demonstrated that bone mineral density (BMD) was highest in patients with hypoparathyroidism, intermediate in controls, and lowest in patients with hyperparathyroidism, confirming that an excess of endogenous PTH is catabolic to bone. The cellular and molecular mechanisms underlying the dual actions of PTH remain to be clearly defined.
Various studies have been undertaken in rats and mice to attempt to create animal models exhibiting the dual actions of PTH. Regarding the anabolic action, it has been well established that intermittent treatment with PTH, both N-terminal 1–34 fragment and intact 1–84 peptide, is anabolic in a range of species including mice (Jilka et al. 1999, Alexander et al. 2001, Andersson et al. 2001, Iida-Klein et al. 2002, Fukata et al. 2004, Rhee et al. 2004, Seebach et al. 2004). However, there are very few studies that demonstrate the catabolic effects of continuously elevated PTH on bone in mice. In ovariectomized rats, Shen et al.(2000) demonstrated that estrogen deficiency induced marked bone loss, and that a 4-week-infusion of rat PTH1–34 induced an additional, significant bone loss in the femur. In the same study, histomorphometric analysis revealed that PTH infusion further increased bone turnover, partially restored bone volume as a percentage of tissue volume and increased cortical porosity in these ovariectomized rats (Zhou et al. 2001). Frolik et al.(2003) have shown that once-daily injection of hPTH1–34 (80 μg/kg per day) increased bone mass in rats, whereas repeated hourly injections over 6 h (6 × (13.3 μg/kg per h)) at a total dose of 80 μg/kg per day PTH decreased bone mass. Imanishi et al.(2001) have created transgenic mice with parathyroid-targeted overexpression of cyclin D1 and demonstrated that these mice exhibited an abnormal relationship between serum calcium and PTH response, similar to that seen in human primary hyperparathyroidism caused by sporadic parathyroid gland hyperplasia (Arnold et al. 2002). Although this transgenic mouse model is an attractive model of hyperparathyroidism, it would also be desirable to develop a model of hyperparathyroidism in wild-type mice that can be produced by simple manipulation or treatment without disruption of genetic structures, allowing studies of the catabolic and anabolic effects of PTH in transgenic mice with various genetic manipulations.
Using 6-week-old female mice, Grey et al.(1999) have shown that a 5-day infusion of hPTH1–84 stimulated interleukin-6 production, which resulted in a significant increase in urinary collagen cross-link levels. This PTH-induced increase in bone resorption was markedly suppressed by interleukin-6 antibody injection and in interleukin-6-knockout transgenic mice, suggesting that interleukin-6 is a mediator of bone-resorbing action of PTH in vivo. Masiukiewicz et al.(2000) demonstrated that ovariectomy increased the catabolic effect of a 5-day hPTH1–84 infusion in mice, and that estrogen treatment prevented this enhanced response to PTH infusion. Few studies in mice have gone beyond 5 days of infusion, and there are no data with regard to the effects of continuous PTH on bone structure or on formation and resorption markers. Therefore, in the present study, we explored the feasibility of delivering PTH continuously by implantation of infusion pumps for up to 14 days and examining various bone measures, and comparing the effects with those of daily subcutaneous injections of hPTH1–34.
Materials and Methods
Materials
hPTH1–34 was purchased from Bachem (Torrance, CA, USA). A diagnostic kit for total serum calcium measurement, ketamine, xylazine and all biochemical reagents were purchased from Sigma Chemicals, Co. (St Louis, MO, USA).
Animals
The experimental protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Helen Hayes Hospital, West Haverstraw, NY, USA. Virgin female C57BL/J6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and stabilized at Helen Hayes Hospital for 2 weeks before the implantation of Alzet pumps (DURECT Corp., Cupertino, CA, USA). Alzet pumps were aseptically filled with appropriate amounts of hPTH1–34 (8.1 pmol/0.25 μl per h, or 40 μg/kg per day equivalent) or vehicle (equivalent volume of 10 mM acetic acid in sterile PBS, pH 7.42) 1 day prior to implantation and stored at 4 °C until use. According to the manufacturer’s guidelines, the pumps were implanted subcutaneously into the back of the neck of mice under anesthesia (ketamine 100 mg/kg/xylazine 3 mg/kg) and the incision closed. All procedures were performed aseptically. After implantation of the pumps, animals were individually housed, given free access to water and fed a standard diet (Purina Mills, St Louis, MO, USA) in a room maintained at 22 °C with 60–75% humidity on a 12-h light/12-h dark cycle, and carefully monitored for any signs of stress, bleeding, pain or abnormal behavior.
Two independent experiments were performed (Table 1). All animals were randomly divided into groups 2 days prior to implantation of the pumps. Experiment 1 was a feasibility experiment to determine whether a 2-week infusion was possible in mice and to compare the murine response to hPTH1–34 with control, vehicle-infused animals. In our pilot trial (Exp1a) we found that in vivo BMD measurement immediately before implantation of the pumps caused marked distress, resulting in loss of three out of five mice with PTH infusion within 2 h of surgical operations. Thus, we performed an additional experiment (Exp1b; control n=4, PTH n=6). BMD was measured 1 day prior to implantation of pumps. Data from experiments 1a and 1b were combined as experiment 1 (control n=9, PTH n=8), as there were no significant within-group differences in BMD and serum biochemical markers between the animals in experiments 1a and 1b. At 2 weeks, bone structure and serum levels of total calcium, hPTH1–34 and endogenous mouse intact PTH (mPTH1–84) were measured. The right femurs in Exp1b (control n=4, PTH n=6) were excised, cleaned, partially embedded in methacrylate and sent to Scanco USA (Wayne, PA, USA) for further analysis of bone microarchitecture and structure assessed by micro-computed tomography (μCT).
Experiment 2 was a short-term comparison of the effects of continuous PTH infusion (n=6) compared with intermittent PTH daily injection (n=6) with BMD and biochemical markers as the outcomes. Baseline BMD was measured 1 day prior to the initiation of treatment.
At euthanasia, blood was collected by cardiac puncture, and serum stored at −80 °C for biochemical assays. For the intermittent treatment, animals were euthanized approximately 20–24 h after the last PTH injection.
BMD measurement by PIXImus
BMD was measured weekly and 1 day prior to initiation of treatment by DXA using PIXImus (GE Lunar Corp., Madison, WI, USA) as previously described (Iida-Klein et al. 2002, 2003). Briefly, mice were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (3 mg/kg), placed prone on the platform of the PIXImus and BMD measured with mouse-specific software (PIXImus, version 1.47). The machine was calibrated daily with the manufacturer’s phantom. The scans were analyzed, and the regions of interest defined as previously described (Iida-Klein et al. 2002, 2003).
μCT analysis
The distal femurs were scanned by Scanco USA using the Desktop Cone-Beam μCT Scanner (μCT40; Scanco USA), with 10 μm isotropic pixel size, 70 kV energy, 114 μA intensity and an integration time of 300 ms. The volume of interest with a length of 1.70 mm was placed in an axial direction in the secondary spongiosa of the distal femurs, just above the growth plate. Pixel dimensions were set at 2048 × 2048 × 170 longitudinally to expose the bone marrow (Laib et al. 2000, 2001). Measured variables their abbreviations were as defined by Parfitt et al.(1987).
Biochemical assays
Serum total calcium was determined in duplicate by colorimetric reaction of calcium ion with o-cresolphthalein complexone in the presence of 8-hydroxyquinoline, and the optical density of this colored compound was measured at 575 nm (Kang et al. 2004). Serum levels of infused hPTH1–34 and endogenous mPTH1–84 were determined using ELISA kits (Immutopics, San Clemente, CA, USA) according to the manufacturer’s instructions. There was no cross-reactivity between the antibodies against hPTH1–34 and mPTH1–84 used in these ELISA kits. Mouse tartrate-resistant acid phosphatase (mTRAP; Immunodiagnostic System, Phoenix, AZ, USA) ELISA assay was performed according to the manufacturer’s instructions. For mouse osteocalcin immunoradiometric assay (Immutopics), 10 μl of serum was diluted 11 times with buffer, and osteocalcin levels were measured using the diluted samples according to the manufacturer’s instructions. Serum creatinine and urea nitrogen (BUN; Thermo Electron Clinical Chemistry, Louisville, CO, USA) were spectrophotometrically measured at 500 and 340 nm, respectively. Mean intra-assay coefficients of variation were 5.6, 3.5, 4.7, 2.4 and 5.0% for calcium, hPTH1–34, mPTH1–84, osteocalcin and mTRAP, respectively.
Statistical analysis
All values for BMD and biochemical marker measurements represent means ± s.e.m. Significant differences between groups were determined by one-way (experiment 1) or two-way (experiment 2) ANOVA (Duncan) using SAS (version 9.1; Cary, NC, USA).
Results
At the end of 2 weeks, there was no significant difference in body weight between groups of animals with vehicle and PTH infusion in all experiments: at 0 weeks, the body weight was 18.27 ± 0.25 and 18.51 ± 0.26 g for animals with vehicle (n=15) and PTH (n=14) infusion (P=0.518), respectively, and at 2 weeks this increased to 20.36 ± 0.32 and 20.1 ± 0.24 g for vehicle and PTH infusion (P=0.511), respectively. No animals showed abnormal movements or signs of stress or discomfort at any point in any experiment.
Experiment 1
Figure 1 shows the serum levels of hPTH1–34 (Fig. 1A) and mPTH1–84 (Fig. 1B) after a 2–week infusion. As expected, no hPTH1–34 was detected in mice infused with vehicle, whereas PTH–infused animals exhibited significant circulating levels of hPTH1–34 (79.79–20.31 pM, P<0.02; Fig. 1A). Infusion of hPTH1–34 significantly suppressed endogenous intact mPTH1–84 from 2.40 ± 0.55 pM (control) to 0.73 ± 0.25 pM (P<0.02; Fig. 1B), and significantly increased total serum calcium levels from 1.95 to 2.64 mM (P<0.005; Fig. 1C). One animal that did not show a detectable level of hPTH1–34 after implantation of the pump containing hPTH1–34 was excluded from all analyses.
There was no significant difference in BMD between control and hPTH1–34-infused mice at 2 weeks at all sites (Table 2). However, using μCT, femurs from mice infused with hPTH1–34 exhibited thinner trabeculae and greater trabecular spacing compared with control mice (Fig. 2). Moreover, hPTH1–34 infusion decreased trabecular connectivity density by 40% (P<0.05; Table 3). There was a trend towards a decrease in trabecular volume, trabecular number and trabecular thickness in mice infused with hPTH1–34 (Table 3).
Experiment 2
As seen in experiment 1, exogenously administered hPTH1–34 was detected only in mice with hPTH1–34 infusion but not in mice with vehicle infusion or daily injection of hPTH1–34 (Fig. 3A). Both infusion and daily injection of PTH suppressed endogenous mPTH1–84 compared with controls (Fig. 3B). Moreover, continuous infusion, but not daily injection of hPTH1–34, produced hypercalcemia (Fig. 3C). Serum creatinine and BUN levels were less than 9 μM and 1.8 mM, respectively, in all groups and there was so significant difference among groups.
The serum osteocalcin level was increased by 43% (P<0.005) with intermittent hPTH1–34 treatment, but not with continuous hPTH1–34 treatment (9% increase, P=0.371; Fig. 4A). The resorption marker, mTRAP, was increased by 223% (P<0.005) and 214% (P=0.066) in mice on intermittent and continuous hPTH1–34 treatment, respectively (Fig. 4B).
There were significant differences in BMD between animals treated with hPTH1–34 in the continuous and intermittent modes of administration at all sites measured at 1 and 2 weeks (Fig. 5). Moreover, there was a slight but significant decrease in femoral BMD in PTH-infused mice compared with that in vehicle-infused mice (Fig. 5B). However, there was no significant difference in BMD between vehicle- and PTH-infused mice at the other skeletal sites.
Discussion
This is the first report demonstrating that a 2-week continuous infusion of hPTH1–34 exerts a catabolic effect on mouse bone with a significant decrease in trabecular connectivity density. Moreover, we showed that whereas both infusion and daily injection of exogenous hPTH1–34 significantly suppressed endogenous mPTH1–84, only PTH infusion induced hypercalcemia at 2 weeks of treatment. Both infusion and daily injection of PTH increased a bone-resorption marker to a similar extent, but only the latter significantly increased a formation marker. We also demonstrated that there was a significant difference in BMD at all sites between continuous infusion and daily injection of PTH.
Intact serum PTH1–84 levels in normal healthy humans range from 1 to 4 pM (mean, 2.4 pM), and increase to 3–20 pM (mean, 8.4 pM) in patients with primary hyperparathyroidism (Rajala et al. 1991), and generally parallel increased serum calcium. In patients and animals with kidney failure, secondary hyperparathyroidism develops and serum PTH levels may exceed 100 pM (Bover et al. 1994, de Francisco 2004). Transgenic mice with parathyroid-targeted overexpression of cyclin D1 exhibit mild hyperparathyroidism, with PTH ranging between 13 and 16 pM – 3–4-fold higher than their age-matched wild-type littermates (2–4 pM) – and a 20–30% increase in total serum calcium (Imanishi et a. 2001, Arnold et al. 2002). However, it takes 12–13 months for this model to exhibit significant differences in biochemical phenotypes between transgenic and wild-type mice (Imanishi et al. 2001). In our current infusion model, intact mPTH1–84 was significantly suppressed, although serum bioactive PTH levels (total PTH=infused hPTH1–34+endogenous intact mPTH1–84) were>100 pM in 7 out of 14 PTH-infused mice. However, serum creatinine and BUN were within the normal range in all groups at the completion of infusion, confirming normal renal function. No animals exhibited abnormal movements or signs of stress or discomfort, and there was no significant difference in body weight between animals treated with vehicle and PTH infusion, with all animals gaining approximately 1.5–2 g during 2 weeks of treatment. Mice with parathyroid-specific cyclin D1 overexpression with mild hyperparathyroidism and hypercalcemia did not exhibit any abnormal phenotype, except changes in calcium balance and biochemical status, and lived longer than 2 years (Imanishi et al. 2001, Arnold et al. 2002). In contrast to this model of chronic, mild hyperparathyroidism, our model may be more useful to define the mechanisms underlying the dual actions of PTH in the short-term and can be applied to a variety of transgenic mice with different phenotypes.
Mice receiving continuous hPTH1–34 infusion exhibited an increase in mTRAP, a bone-resorption marker, that was similar to those receiving daily hPTH1–34 injection (214 versus 238% increase), but failed to show a significant increase in a bone-formation marker, osteocalcin. Thus, PTH infusion-induced hypercalcemia may be primarily due to stimulated resorption without any disturbance of kidney function. Since it has been considered that osteocalcin is a later formation marker, use of other, earlier formation markers in a short-term study may be more appropriate. Moreover, we only examined the biochemical markers at the endpoint of the study. Development of better assay systems that can measure bone-formation and -resorption markers in smaller blood samples from live mice at earlier time points will be helpful for future studies.
In the current study, endogenous, intact mPTH1–84 was significantly reduced by both intermittent and continuous PTH treatment. This is consistent with observations in human studies (Cosman et al. 1991, Lindsay et al. 1993).
The rodent skeletal response to the catabolic action of PTH is very sensitive to estrogen status in both rats (Shen et al. 1993, Zhou et al. 2001) and mice (Masiukiewicz et al. 2000). In the present study, in which the mice were not ovariectomized, it is possible that endogenous estrogen may have blocked the catabolic effects of PTH infusion on bone mass. This may be one explanation for why no clear catabolic effect of PTH infusion was observed by densitometry in the PTH-infused mice, although μCT analysis revealed a significantly reduced trabecular connectivity density. Based on these observations, we speculate that BMD measurement by DXA may be too insensitive to detect the mild, early catabolic effects produced by continuous PTH treatment, although it can easily detect the more dramatic, anabolic effects of intermittent PTH treatment.
Further investigation is required to establish PTH infusion as a murine model of hyperparathyroidism, including the temporal changes in serum calcium and bone markers, dose dependence, static and dynamic histomorphometry and vitamin D status. However, the current study clearly demonstrated the feasibility of this approach, and indicated that short-term infusion with hPTH1–34 might hold significant promise as a murine model to study the cellular and molecular mechanisms of the catabolic action of PTH in animals with relatively normal physiology and without complicated genetic manipulation.
Experimental protocol
| (a) Experiment 1: pilot studies of 2-week infusion of hPTH1–34 | ||||
|---|---|---|---|---|
| Age (weeks) | n | Treatment | Euthanasia (weeks) | |
| Group | ||||
| Experiment 1a | ||||
| A. Control | 10 | 5 | Vehicle infusion, 14 days | 12 |
| B. PTH | 10 | 2 | (8.1 pmol/0.25 μl per h)×14 days | 12 |
| Experiment 1b | ||||
| A. Control | 10 | 4 | Vehicle infusion, 14 days | 12 |
| B. PTH | 10 | 6 | (8.1 pmol/0.25 μl per h)×14 days | 12 |
| (b) Experiment 2: comparison between intermittent and continuous hPTH1–34 treatment | ||||
|---|---|---|---|---|
| Age (weeks) | n | Treatment | Euthanasia (weeks) | |
| One of the PTH infusion mice in experiment 1b showed no detectable hPTH1–34 levels, so all data from this animal were excluded from analysis. | ||||
| Group | ||||
| C. Basal | 10 | 6 | 10 | |
| D. Control injection | 10 | 6 | Vehicle infusion, 14 days | 12 |
| E. PTH injection | 10 | 6 | hPTH1–34 (40 μg/kg per day)×14 days | 12 |
| F. Control infusion | 10 | 6 | Vehicle infusion, 14 days | 12 |
| G. PTH infusion | 10 | 6 | (8.1 pmol/0.25 μl per h)×14 days | 12 |
Effect of a 2-week infusion of hPTH1–34 on BMD in C57BL/J6 mice
| Time of BMD measurement (mg/cm2) | |||
|---|---|---|---|
| 0 weeks | 1 week | 2 weeks | |
| Animals were treated continuously with vehicle or hPTH1–34 as described in the Materials and Methods section. (n=9 for control vehicle infusion, n=7 for PTH infusion). | |||
| Sites | |||
| Femur | |||
| Control infusion | 56.83 ± 0.71 | 54.88 ± 0.74 | 55.38 ± 1.00 |
| PTH infusion | 57.29 ± 0.44 | 53.67 ± 0.51 | 55.97 ± 0.50 |
| Tibia | |||
| Control infusion | 41.26 ± 0.55 | 39.08 ± 0.33 | 40.75 ± 0.80 |
| PTH infusion | 41.31 ± 0.48 | 39.93 ± 0.23 | 40.83 ± 0.71 |
| Lumbar vertebrae 4–5 | |||
| Control infusion | 51.39 ± 0.97 | 49.77 ± 0.78 | 49.84 ± 1.46 |
| PTH infusion | 53.80 ± 0.58 | 49.80 ± 1.04 | 49.33 ± 1.25 |
Effects of hPTH1–34 infusion on bone structure
| Control | PTH | P value | |
|---|---|---|---|
| Vox, Based on counting voxels; SMI, 0 for parallel plates, 3 for cylindrical rods; TRI, based on triangulatization of surface (one more interpolation step), assuming that bone is made of parallel plates, two-dimensional histomorphometry; DT, based on distance transformation (filling structure with spheres), without plate model assumption, three-dimensional histomorphometry; BV/TV, bone volume as a percentage of tissue volume; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation. | |||
| Vox BV/TV (%) | 8.2 ± 0.7 | 6.4 ± 0.4 | 0.1 |
| Connectivity density (1/mm3) | 92.64 ± 12.14 | 55.56 ± 8.08 | <0.05 |
| TRI-SMI (structure model index) | 2.67 ± 0.14 | 3.06 ± 0.06 | 0.06 |
| TRI-bone surface (mm2) | 13.55 ± 1.64 | 10.52 ± 0.53 | 0.16 |
| TRI-BV/TV (%) | 7.7 ± 0.7 | 5.9 ± 0.4 | 0.09 |
| TRI-Tb.N (1/mm) | 2.66 ± 0.24 | 2.19 ± 0.09 | 0.15 |
| TRI-Tb.Th (μm) | 28.8 ± 0.7 | 26.7 ± 0.6 | 0.08 |
| TRI-Tb.Sp (μm) | 358 ± 39 | 433 ± 20 | 0.16 |
| DT-Tb.N (1/mm) | 4.27 ± 0.17 | 4.23 ± 0.10 | 0.86 |
| DT-Tb.Th (μm) | 38.6 ± 1.2 | 37.5 ± 0.6 | 0.48 |
| DT-Tb.Sp (μm) | 234 ± 11 | 236 ± 6 | 0.90 |
Effects of a 2-week infusion with hPTH1–34 on serum hPTH1–34 (A), mPTH1–84 (B) and total calcium (C) in female C57BL/J6 mice. Animals were continuously treated with hPTH1–34 (8.1 pmol/0.25 μl per h) using Alzet pumps and blood collected for biochemical assays as described in the Materials and Methods section. All samples were assayed in duplicate, and averaged. Values are means ± s.e.m. (n=9 for control vehicle infusion, n=8 for PTH infusion).
Citation: Journal of Endocrinology 186, 3; 10.1677/joe.1.06270
Trabecular bone microarchitecture by μCT analysis in the distal femur from vehicle-infused (A) and hPTH1–34-infused (B) mice.
Citation: Journal of Endocrinology 186, 3; 10.1677/joe.1.06270
Comparison of the effects of continuous and intermittent treatment with hPTH1–34 on hPTH1–34 (A), mPTH1–84 (B) and total serum calcium levels (C). Animals were treated and blood collected for biochemical assays as described in the Materials and Methods section. Values are means ± s.e.m. from six mice. Serum levels of hPTH1–34, mPTH1–84 and total calcium of basal mice were 0 pM, 1.71 ± 0.21 pM and 2.37 ± 0.11 mM, respectively, and were not significantly different from the values of vehicle injection or infusion.
Citation: Journal of Endocrinology 186, 3; 10.1677/joe.1.06270
Comparison of the effects of continuous and intermittent treatment with hPTH1–34 on bone-formation (A) and -resorption markers (B). Animals were treated and blood collected for biochemical assays as described in the Materials and Methods section. Values are means ± s.e.m. from six mice.
Citation: Journal of Endocrinology 186, 3; 10.1677/joe.1.06270
Comparison of the effects of continuous versus intermittent treatment with hPTH1–34 on BMD. Animals were treated either intermittently or continuously with hPTH1–34 and BMD was measured weekly by PIXImusTM as described in the Materials and Methods section. Definition of the regions of interest was described elsewhere (Iida-Klein et al. 2002, 2003). Each scan was analyzed twice and averaged (n=6 for each group). LV4–5, lumbar vertebrae 4–5.
Citation: Journal of Endocrinology 186, 3; 10.1677/joe.1.06270
We thank Dr T J Hahn for critically reviewing the manuscript. We are also grateful to Mrs E Vasquez for her assistance with statistical analysis. This work was supported in part by an NIH/NIAMS grant (AR39191), unrestricted research grants from Bristol Myers Squibb, NS Pharma, and the Helen Hayes Hospital Foundation. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.
References
Alexander JM, Bab I, Fish S, Müller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M et al.2001 Human parathyroid hormone 1–34 reverses bone loss in ovariectomized mice. Journal of Bone and Mineral Research 16 1665–1673.
Andersson N, Lindberg MK, Ohlsson C, Andersson K & Ryberg B 2001 Repeated in vivo determination of bone mineral density during parathyroid hormone treatment in ovariectomized mice. Journal of Endocrinology 170 529–537.
Arnold A, Shattuck TM, Mallya SM, Krebs LJ, Costa J, Gallagher J, Wild Y & Saucier K 2002 Molecular pathogenesis of primary hyperparathyroidism. Journal of Bone and Mineral Research 17 Suppl 2 N30–N36.
Bilezikian JP & Silverberg SJ 2004 Clinical practice. Asymptomatic primary hyperparathyroidism. New England Journal of Medicine 350 1746–1751.
Bilezikian JP, Brandi ML, Rubin M & Silverberg SJ 2005 Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. Journal of Internal Medicine 257 6–17.
Bover J, Jara A, Trinidad P, Rodriguez M, Martin-Malo A & Felsenfeld AJ 1994 The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia. Kidney International 46 310–317.
Chen Q, Kaji H, Iu MF, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T & Chihara K 2003 Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. Journal of Clinical Endocrinology and Metabolism 88 4655–4658.
Cosman F, Shen V, Herrington B & Lindsay R 1991 Response of the parathyroid gland to infusion of human parathyroid hormone-(1–34) [PTH-(1–34)]: demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1–84) assay. Journal of Clinical Endocrinology and Metabolism 73 1345–1351.
Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V & Lindsay R 2001 Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after PTH withdrawal. Journal of Bone and Mineral Research 16 925–931.
Dobnig H 2004 A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expert Opinion on Pharmacotherapy 5 1153–1162.
Duan Y, De Luca V & Seeman E 1999 Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone. Journal of Clinical Endocrinology and Metabolism 84 718–722.
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H & Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. New England Journal of Medicine 349 1216–1226.
de Francisco AL 2004 Secondary hyperparathyroidism: review of the disease and its treatment. Clinical Therapeutics 26 1976–1993.
Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown-Augsburger PL, Sato M & Hock JM 2003 Anabolic and catabolic bone effects of human parathyroid hormone (1–34) are predicted by duration of hormone exposure. Bone 33 372–379.
Fukata S, Hagino H, Okano T, Yamane I, Kameyama Y & Teshima R 2004 Effect of intermittent administration of human parathyroid hormone on bone mineral density and arthritis in rats with collagen-induced arthritis. Arthritis and Rheumatism 50 4060–4069.
Grey A, Mitnick M, Shaspes S, Gundberg C, Ellison A & Insogna K 1996 Circulating levels of interleukin-6 and tumor-necrosis factor-a are elevated in primary hyperparathyroidism, and correlate with markers of bone resorption. Journal of Clinical Endocrinology and Metabolism 81 3450–3454.
Grey A, Micnick M-A, Masiukiewicz U, Sun B-H, Rudikoff S, Jilka RL, Manolagas SC & Insogna K 1999 A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 140 4683–4690.
Iida-Klein A, Zhou H, Lu SS, Levine L, Ducayen-Knowles M, Dempster DW, Nieves J & Lindsay R 2002 Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. Journal of Bone and Mineral Research 17 808–816.
Iida-Klein A, Yokoyama K, Lu S-S, Dempster DW, Nieves J & Lindsay R 2003 Precision, accuracy and reproducibility of dual-X-ray absorptiometry (DXA) in mice in vivo. Journal of Clinical Densitometry 6 25–33.
Imanishi Y, Hosokawa Y, Yoshimoto K, Schipani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard F et al.2001 Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. Journal of Clinical Investigation 10 1093–1102.
Jilka RL, Weinstein RS, Bellido T, Robertson P, Parfitt AM & Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. Journal of Clinical Investigation 10 439–446.
Kang HP, Scott MG, Joe BN, Narra V, Heiken J & Parvin CA 2004 Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method. Clinical Chemistry 5 741–746.
Laib A, Barou O, Vico L, Lafage-Proust MH, Alexandre C & Rügsegger P 2000 3-D micro-computed tomography of trabecular and cortical bone architecture with application to a rat model of immobilization osteoporosis. Medical and Biological Engineering and Computing 3 326–332.
Laib A, Kumer JL, Majumdar S & Lane NE 2001 The temporal changes of trabecular architecture in ovariectomized rats assessed by microCT. Osteoporosis International 1 936–941.
Lindsay R, Nieves J, Henneman E, Shen V & Cosman F 1993 Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1–34): kinetics and biochemical response in estrogenized osteoporotic patients. Journal of Clinical Endocrinology and Metabolism 7 1535–1539.
Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D & Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 35 550–555.
Masiukiewicz US, Mitnick M, Grey AB & Insogna KL 2000 Estrogen modulates parathyroid hormone-induced interleukin-6 production in vivo and in vitro. Endocrinology 141 2526–2531.
Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM & Recker RM 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Journal of Bone and Mineral Research 2 595–610.
Rajala MM, Klee GG & Heath III H 1991 Calcium regulation of parathyroid and C cell function in familial benign hypercalcemia. Journal of Bone and Mineral Research 6 117–124.
Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC et al.1980 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. British Medical Journal 280 1340–1344
Rhee Y, Won YY, Baek MH & Lim SK 2004 Maintenance of increased bone mass after recombinant human parathyroid hormone (1–84) with sequential zoledronate treatment in ovariectomized rats. Journal of Bone and Mineral Research 19 931–937.
Seebach C, Skripitz R, Andreassen TT & Aspenberg P 2004 Intermittent parathyroid hormone (1–34) enhances mechanical strength and density of new bone after distraction osteogenesis in rats. Journal of Orthopaedic Research 22 472–478.
Shen V, Dempster DW, Birchman R, Xu R & Lindsay R 1993 Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. Journal of Clinical Investigation 91 2479–2487.
Shen V, Birchmann R, Wu DD & Lindsay R 2000 Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion. Journal of Bone and Mineral Research 15 740–746.
Zhou H, Shen V, Dempster DW & Lindsay R 2001 Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat. Journal of Bone and Mineral Research 16 1300–1307.
